ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

napazimone

Also written as “KL1333”, “Napazimone” and “KL1333 25 mg”.

Its studies are mostly in Mitochondrial Diseases · MELAS Syndrome · Muscular Diseases, led by 2 companies.

Drug pageNapazimone: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Dec 6, 20225 company-led studies, 2 open or runningNext primary completion: Oct 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pharming Group42 open or runningphase 2since Dec 6, 2022Mar 19, 2019Oct 2027phase 2 · NCT05650229
Yungjin Pharm.its history only10 open or runningphase 1since Feb 5, 2017Feb 5, 2017none ahead

Also a collaborator on its studies: ICON.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pharming Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Mar 19, 2019First study: phase 1 study in Mitochondrial DiseasesFirst studyNCT03888716 · 72 enrolled · United Kingdom
  2. Nov 13, 2020Phase 1 study in Mitochondrial DiseasesNCT04643249 · 14 enrolled · United Kingdom
  3. Dec 6, 2022Phase 2 study in Muscular DiseasesNCT05650229 · 180 planned · United States, Australia, Belgium and more
  4. Aug 11, 2024Named napazimoneINNProposed as its International Nonproprietary Name in WHO's List 131 · before, KL1333
  5. Feb 24, 2026Phase 2 study in Mitochondrial DiseasesNCT07514338 · 140 planned · United States, Belgium, Czechia and more

Ahead

  1. Oct 2027Primary completion: phase 2 study in Muscular DiseasesNCT05650229
  2. Mar 31, 2029Primary completion: phase 2 study in Mitochondrial DiseasesNCT07514338

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 Pharming Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07514338Mitochondrial Diseases · United States, Belgium, Czechia and more2RecruitingMar 31, 2029140
NCT05650229Muscular Diseases · United States, Australia, Belgium and more2RecruitingOct 2027180
NCT04643249Mitochondrial Diseases · United Kingdom1CompletedDec 17, 202014
NCT03888716Mitochondrial Diseases · United Kingdom1CompletedMar 16, 202172

How it is read

Names in the registry

  • “KL1333”, 3 entries
  • “Napazimone”, 1 entry
  • “KL1333 25 mg”, 1 entry
  • “KL1333 50 mg”, 1 entry
  • “KL1333 100 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.